United Therapeutics/UTHR

$272.88

-1.3%
-
1D1W1MYTD1YMAX

About United Therapeutics

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

Ticker

UTHR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Martine Rothblatt

Employees

1,168

Headquarters

Silver spring, United States

UTHR Metrics

BasicAdvanced
$12B
Market cap
13.02
P/E ratio
$21.13
EPS
0.50
Beta
-
Dividend rate
$12B
0.4998
$279.98
$204.44
535K
3.775
3.635
3.747
11.24
11.5
16.36%
20.08%
18.03%
13.023
4.886
2.279
2.337
16.223
26.09%
42.24%
16.2%
19.74%

What the Analysts think about UTHR

Analyst Ratings

Majority rating from 16 analysts.
Buy

Price Targets

Average projection from 13 analysts.
10.29% upside
High $400.00
Low $220.00
$272.88
Current price
$300.95
Average price target

UTHR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
45.24% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$678M
10.25%
Net income
$307M
41.23%
Profit margin
45.24%
28.12%

UTHR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.18%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$5.24
$5.38
$4.36
$6.17
-
Expected
$4.51
$5.04
$4.19
$5.65
$6.24
Surprise
16.3%
6.69%
4.16%
9.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for United Therapeutics stock?

United Therapeutics (UTHR) has a market cap of $12B as of May 25, 2024.

What is the P/E ratio for United Therapeutics stock?

The price to earnings (P/E) ratio for United Therapeutics (UTHR) stock is 13.08 as of May 25, 2024.

Does United Therapeutics stock pay dividends?

No, United Therapeutics (UTHR) stock does not pay dividends to its shareholders as of May 25, 2024.

When is the next United Therapeutics dividend payment date?

United Therapeutics (UTHR) stock does not pay dividends to its shareholders.

What is the beta indicator for United Therapeutics?

United Therapeutics (UTHR) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the United Therapeutics stock price target?

The target price for United Therapeutics (UTHR) stock is $300.95, which is 10.29% above the current price of $272.88. This is an average based on projections from 13 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell United Therapeutics stock

Buy or sell United Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing